CubaPLUS Magazine

A new treatment using Biomodulina T has a significant impact on the quality of life of Cuban families

Biomodulina T is a top-quality, fully Cuban medicine that has been effectively used for three decades with immunomodulatory effects in adults –it was even used to boost the immune system during the COVID-19 pandemic. It now has a new application that reduces infections in children, which is a major event in the health sector, as it had not been used in minors until now.

In a meeting with Dr. Odalis María de la Guardia Peña, the leading specialist at the forefront of the trial that demonstrated the drug’s effectiveness in infants, she detailed the work done by the team of professionals in charge of the study, whose final results indicate that Biomodulina T is an effective and safe medicine in the treatment of thymus hypoplasia.

The thymus is the primary organ responsible for the production, maturation, and selection of immunocompetent T lymphocytes. Aplasia or hypoplasia of this organ leads to the emergence of immunodeficiency, being one of the bestknown causes of disorders in the normal development of the thymus, known as DiGeorge Syndrome, hence the importance of combating this disease.

According to Dr. De la Guardia, a total of 60 patients–children of both sexes–with varying degrees of affection from the disease received treatment with Biomodulina T, which resulted in an increase of more than 60% in the thymus area in each of the treated patients; 83.3% of patients achieved a normal value.

Furthermore, infections were reduced by 81.6%, with a significant effect on both viral and bacterial infections, therefore decreasing the consumption of antibiotics, an effect statistically associated with the increase in the thymus area.

For those suffering from immunodeficiency, Biomodulina T induced a slight increase in the cellular immune response in terms of the lymphocyte subpopulations CD3+/ CD4+ and CD3+/CD8+, while reactions to the medicine were minimal.

This was the first study to incorporate a WHOvalidated questionnaire to assess Quality of Life in the pediatric patient with immunodeficiency and was conducted by a group of outstanding specialists from the pediatric hospitals in Havana, “Ángel Arturo Aballí” and “William Soler,” respectively, as well as the National Coordinating Center for Clinical Trials (CENCEC) and the National Center for Biopreparations (BIOCEN), the entity that produces the medicine, which was registered in 2008.

The results achieved with Biomodulina T are further evidence of the scientific level reached by the Cuban health sector, which continues to advance relentlessly in favor of improving the quality of life of the country’s population, always thinking that “Health is a right for all.”